Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Tradr 2X Long SRPT Daily ETF

SRPU

5.8850.00% ( 0.000 )

Delisted: Jun 11, 16:00:00 (EDT)

OverviewOverview OptionsOptions NewsNews PostsPosts WikiWiki RatingsRatings CompositionComposition DividendsDividends

LongbridgeAI

Weekly Recap | Sarepta Therap +7.86%, most brokers rate it hold
Weekly Review·1 day ago, 08:03 AM
SRPT-2.13%
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
Unusual Whales·1 day ago, 03:29 AM
SRPT-2.13%SRPU0.00%
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 6.6% - Should You Buy?
Market Beat·Sep 2 at 04:41 PM
SRPT-2.13%SRPU0.00%
US Biotech Firms Advance Pipelines as Vertex and Illumina Raise 2026 Forecasts
Global Report·Sep 1 at 11:32 AM
REGN-1.87%VRTX-2.12%
Unconventional Transitions: Inside the Latest Overhauls at Aurora, Logitech and AI Financial
Global Report·Sep 1 at 09:18 AM
AIFC-0.95%AUR+0.32%
Sarepta to present at Morgan Stanley Global Healthcare Conference fireside chat
PUBT·Aug 31 at 08:30 PM
MS+0.26%SRPT-2.13%
Deutsche Bank AG Takes $2.04 Million Position in Sarepta Therapeutics, Inc. $SRPT
Market Beat·Aug 29 at 08:05 AM
SRPT-2.13%DB-0.55%
Sarepta Therapeutics (SRPT) Could Be 30% Undervalued After Elevidys Progress Hopes
Simplywall·Aug 28 at 08:19 AM
SRPT-2.13%SRPU0.00%
10 Health Care Stocks With Whale Alerts In Today’s Session
benzinga_article·Aug 27 at 05:35 PM
CNC-1.44%AMGN-1.55%
Cross-Sector AI and Restructuring Moves: What's Next for Pinterest and Lyft
Global Report·Aug 25 at 11:33 AM
PINS-2.16%LYFT-3.24%
BioPharma Shuffle: Amgen's Secret Overhaul and CRISPR's Next Big Catalyst
Global Report·Aug 25 at 09:21 AM
- US biopharmaceutical and medical device companies are accelerating core pipelines and experiencing leadership changes ahead of the 2026 commercialization window. - Amgen restructured to focus resources, Regeneron faced legal pressure alongside an FDA approval, CRISPR Therapeutics gained attention from expanded indications, Sarepta appointed a new CEO, and Iovance reported strong Q2 earnings driven by its TIL therapy. - Zai Lab achieved positive 3 phase trial results while Novavax suffered revenue declines due to the revocation of its old COVID-19 vaccine emergency use authorization.
AMGN-1.55%REGN-1.87%
The Biotech Crossroads: Inside Sarepta's Shakeup and Vor's Pivot
Global Report·Aug 19 at 09:43 AM
SRPT-2.13%VOR+3.34%
The biotech boom's fatal blind spots
Global Report·Aug 19 at 09:42 AM
SRPT-2.13%CLOV0.00%
US Rare Disease Biotechs Navigate Regulatory Scrutiny and Revised 2026 Guidance
Global Report·Aug 13 at 09:42 AM
SRPT-2.13%
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)
Tip Ranks·Aug 6 at 11:19 AM
SRPT-2.13%SRPU0.00%